Cáncer de ovario

  1. Pérez Martelo, M. 1
  2. Cebey López, V. 1
  3. Mateos González, M. 1
  4. Cueva Bañuelos, J.F. 1
  1. 1 Servicio de Oncología Médica y Grupo de Oncología Médica Traslacional, Hospital Clínico Universitario e Instituto de Investigación Sanitaria-CIBERONC, Santiago de Compostela, La Coruña, España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2021

Issue Title: Enfermedades oncológicas (IV)Melanoma, cáncer de mama y tumores ginecológicos

Series: 13

Issue: 27

Pages: 1518-1526

Type: Article

DOI: 10.1016/J.MED.2021.03.003 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Sustainable development goals

Abstract

Ovarian cancer is the second most common gynecologic neoplasm and causes the greatest mortality. High-grade serous carcinoma is the most frequent histological subtype. Its clinical presentation tends to be insidious, such that in the majority of cases, diagnosis is made with advanced intra-abdominal disease. Surgical staging and primary cytoreductive surgery conducted by an experienced team followed by adjuvant platinum- and taxane-based chemotherapy is the most used therapeutic technique, especially in cases in earlier stages. On occasion, chemotherapy is occasionally administered prior to interval debulking surgery, especially in advanced disease. The majority of patients in advanced stages will have recurrence and will require additional treatment. In addition to platinum- and taxane-based chemotherapy, new drugs such as bevacizumab and, in particular, PARP inhibitors have improved outcomes. They are particularly effective when BRCA mutations are present and in both first-line treatment and recurrence.

Bibliographic References

  • Las cifras cáncer del cáncer en España 2019. Publicado por la Sociedad Española de Oncología Médica (SEOM).
  • Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482-90.
  • Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO Guideline. J Clin Oncol. 2020;38:1222-45.
  • Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296(2):185-92.
  • Lacey JV, Sherman ME. Ovarian neoplasia. En: Robboy SL, Mutter GL, Prat J, eds. Robboy’s pathology of the female reproductive tract. 2ª ed. Oxford: Churchill Livingstone Elsevier; 2009. p. 601.
  • Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2018;143Suppl2:59-78.
  • Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15.
  • Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-7.
  • Winter WE, III, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26(1):83-9.
  • Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol. 2006;100:33-7.
  • Xu K, Yang S, Zhao Y. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta analysis. Oncotarget. 2017;8(1):285-302.
  • Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al. «BRCAness» syndrome in ovarian cancer: a case control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26(34):5530-6.
  • Musto A, Rampin L, Nanni C, Marzola MC, Fanti S, Rubello D. Present and future of PET and PET/CT in gynaecologic malignancies. Eur J Radiol. 2011;78:12-20.
  • Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007;25(20):2873-83.
  • Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, et al. Fith ovarian cancer consensus conference of the gynecologic intergroup: first line interventions. Ann Oncol. 2017;28:711-7.
  • Lawrie TA, Winter Roach BA, Heus P, Kitchener HC. Adjuvant (postsurgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2015;2015(12):CD004706.
  • AJCC Cancer Staging Manual. 8th ed. Chicago: Springer;2017. p. 681-90.
  • Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21(4):750-5.20.
  • Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95Suppl1:S161-92.
  • Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003;197:198-205.
  • Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380:822-32.
  • Maggioni A, Benedetti Panici P, Dell’Anna T, Landoni F, Lissoni A, Pellegrino A,et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95:699-704.
  • Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560-6.
  • Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289-95.
  • Du Bois A, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol. 2020;38Suppl15: 6000.
  • Zang R, Zhu J, Shi T, Liu J. A randomized phase III trial of secondary cytoreduction in late recurrent ovarian cancer: a Shanghai Gynecologic Ovarian Group. J Clin Oncol. 2020;38Suppl15:6001.
  • Bickell NA, Egorova N, Prasad Hayes M, Franco R, Howell EA, Wisnivesky J, et al. Secondary surgery versus chemotherapy for recurrent ovarian cancer. Am J Clin Oncol. 2018;41(5):458-64.
  • Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;2013(2):CD008765.
  • Elit L, Chambers A, Fyles A, Covens A, Carey M, Fung MF. Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer. 2004;101:1926-35.
  • Winter Roach BA, Kitchener HC, Lawrie TA. Adjuvant (postsurgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2012 Mar 14;3(3):CD004706.
  • Trimbos B, Timmers P, Pecorelli S, Coens C, Ven K, van der Burg M, et al. Surgical staging and treatment of early ovarian cancer: long term analysis from a randomized trial. J Natl Cancer Inst. 2010;102:982-7.
  • Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006; 102(3):432-9.
  • Kyrgiou M, Salanti G, Pavlidis N, Ioannidis JP. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta analysis of multiple treatments. J Natl Cancer Inst. 2006; 98:1655-63.
  • Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long term results of dose dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open label trial. Lancet Oncol. 2013;14(10): 1020-6.
  • Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016 Jan 12;(1):CD005340.
  • Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, Di Silvestro PA, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019;37:1380-90.
  • Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018;378:230-40.
  • Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-83.
  • Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-96.
  • Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Fried-lander M, et al. maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495-505.
  • González Martín A, Pothuri B, Vergote I, De Pont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391-402.
  • Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381:2403-15.
  • Ray Coquard I, Pautier P, Pignata S, Pérol D, González Martín A, Berger R, et al. Olaparib plus bevacizumab as first line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416-28.
  • Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-53.
  • Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes P, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open label, randomised, controlled, non inferiority trial. Lancet. 2015;386:249-57.
  • Coleridge SL, Bryant A, Lyons TJ, Goodall RJ, Kehoe S, Morrison J. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 2019; 2019.
  • Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? Gynecol Oncol. 2013;128:6-11.
  • Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:3460-73.
  • McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, et al. Fith ovarian cancer consensus conference of the gynecologic intergroup: individualized therapy and patient factors. Ann Oncol. 2017;28:702-10.
  • Raja FA, Counsell N, Colombo N, Pfisterer J, du Bois A, Parmar MK, et al. Platinum versus platinum combination chemotherapy in platinum sensitive recurrent ovarian cancer: a meta analysis using individual patient data. Ann Oncol. 2013;24(12):3028-34.
  • Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann On-col. 2011;22(1):39-48.
  • Colombo N, Gadducci A, Sehouli J, Biagioli E, Nyvang G, Riniker S, et al. INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line Ann Oncol. 2020;31Suppl4: S1142-215.
  • Pignata S, Scambia G, Raspagliesi R, Murgia V, Pisano C, Salutari V, et al. The MITO8 phase 3 international multicenter randomized study testing the effect on survival of prolonging platinum free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG. J Clin Oncol. 2016; 34Sppl15:5505.
  • Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidzin ́ ski M, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum sensitive relapsed ovarian cancer and a germline BRCA1/2 Mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38:1164-74.
  • Mirza MR, Avall Lundqvist E, Birrer MJ, de Pont Christensen R, Nyvang GB, Malander S, et al. Niraparib plus bevacizumab versus niraparib alone for platinum sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019;20(10):1409-19.
  • Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: A randomized, double blind, placebo controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039-45.
  • Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779-91.
  • Pfisterer J, Dean AP, Baumann K, Rau J, Harter P, Joly F, Seouli J, et al. Carboplatin/pegylated liposomal doxorubicin/bevacizumab vs carboplatin/gemcitabine/bevacizumab in patients with recurrent ovarian cancer. A prospective randomized phase III ENGOT/GCIG Intergroup study. ESMO. 2018;29Suppl8: VIII332-33.
  • Pujade Lauraine E, Ledermann J, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum.sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double blind, randomised, placebo controlled, phase 3 trial. Lancet Oncol. 2017;18: 1274-84.
  • Mirza MR, Pignata S, Ledermann JA. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann Oncol. 2018;29:1366-76.
  • Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double blind, placebo controlled, phase 3 trial. Lancet. 2017;390:1949-61.
  • Pujade Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum resistant recurrent ovarian cancer: The AURELIA open label randomized phase III trial. J Clin Oncol. 2014;32:1302.
  • Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2001;CD001034.
  • Gershenson DM, Miller A, Brady W, Paul J, Carty K, Rodgers W, et al. A randomized phase II/iii study to assess the efficacy of trametinib in patients with recurrent or progressive low grade serous ovarian or peritoneal cancer. Ann Oncol. 2019;30Suppl5:v851-934.
Data source: Dialnet